Teva introduces authorized generic Flector Patch
Teva is introducing its authorized generic of Pfizer's Flector patch (diclofenac epolamine topical patch, 1.3%.)
It is a nonsteroidal anti-inflammatory drug, that is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions.
“The launch of our authorized generic of Flector Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” Teva executive vice president and head of North America commercial Brendan O’Grady said.
Flector patch has a market value of $123 million, according to IQVIA December 2018 data.
It is a nonsteroidal anti-inflammatory drug, that is indicated for the topical treatment of acute pain due to minor strains, sprains and contusions.
“The launch of our authorized generic of Flector Patch in the U.S. is an important addition to Teva’s portfolio of over 40 generic pain management medicines,” Teva executive vice president and head of North America commercial Brendan O’Grady said.
Flector patch has a market value of $123 million, according to IQVIA December 2018 data.